Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities.
Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies.
Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.
